Evidence remains inconclusive about the association of systemic inflammatory markers with colorectal neoplasia. We investigated whether circulating inflammatory markers were associated with risk of advanced colorectal adenoma. We measured plasma macrophage inhibitory cytokine-1 (MIC-1), C-reactive protein (CRP), interleukin-6 (IL6), and soluble TNF receptor 2 (sTNFR-2) in blood samples drawn from 32,826 women in 1989 to 1990 in the Nurses' Health Study. Through 2008, we documented 757 cases of advanced colorectal adenomas (≥1 cm or any size with advanced histology); each case was matched by age and time of blood draw with one control randomly selected from participants who underwent lower endoscopy and did not have neoplasia. Plasma MIC-1 was associated with higher risk of advanced adenoma (Ptrend = 0.04), with an OR of 1.55 (95% confidence interval, 1.03–2.32) comparing extreme quintiles of MIC-1 after adjusting for colorectal cancer–risk factors and other inflammatory markers. Among cases, MIC-1 level was positively associated with the number of adenomas (P < 0.001) and gradually increased from adenomas located in the rectum, distal colon, and up to the proximal colon. There was a strong positive association between MIC-1 and risk of adenomas with multiplicity, ≥1 cm size and location in the proximal colon (all Ptrend < 0.05). CRP, IL6, or sTNFR-2 was not associated with adenoma risk. In conclusion, plasma MIC-1 was associated with higher risk of colorectal adenoma, especially multiple, large, and proximal adenomas. Our results provide further support for a role for MIC-1 in carcinogenesis and the potential for MIC-1 as an adjunctive biomarker for detection of advanced colorectal adenoma. Cancer Prev Res; 9(1); 27–34. ©2015 AACR.

Colorectal cancer is the third most commonly diagnosed cancer and the fourth leading cause of cancer-related death in the world (1). Inflammation has been implicated in the initiation and progression of colorectal cancer (2). Patients with ulcerative colitis and Crohn's colitis demonstrate chronic inflammation in the gastrointestinal mucosa and are at increased risk of developing colorectal cancer (3). Conversely, regular use of anti-inflammatory medications such as aspirin has been associated with lower risk of colorectal cancer (4) as well as colorectal adenomas (5–8), precursors of most colorectal cancer.

Despite the preponderance of evidence implicating chronic inflammation in colorectal carcinogenesis, epidemiologic data remain inconclusive about the association between systemic inflammatory markers and colorectal neoplasia. Circulating C-reactive protein (CRP), a liver-derived acute phase protein that is elevated in chronic inflammatory conditions, has been associated with an increased risk of colorectal cancer in 7 (9–15) of the 18 prospective studies that have been published to date (9–25). Studies examining the association of other inflammatory cytokines, such as interleukin-6 (IL6; refs. 10, 22–24, 26) and TNFα (23, 26, 27), with colorectal cancer are limited and inconsistent. Recently, macrophage inhibitory cytokine-1 (MIC-1, also known as growth differentiation factor 15, GDF15), a divergent member of the human TGFβ superfamily and a mediator of the systemic inflammatory response (28), has been related to development of cancers in various organs (29–32), including colorectal cancer (33). We recently showed that elevated levels of plasma MIC-1 were associated with higher risk of incident colorectal cancer (34).

However, there are limited data about the association of inflammatory markers with colorectal adenomas. The 5 studies that have prospectively assessed the relationship between circulating CRP and colorectal adenomas have each reported null associations (35–38) except one study, which observed an inverse association between serum CRP and risk of adenomas (39). In the Polyp Prevention Study, serum MIC-1 was associated with the presence of colorectal adenomas and their recurrence 3 years later. However, this analysis was limited by the large variation in the time of MIC-1 measurement with respect to colonoscopy, which compromises its ability to determine whether MIC-1 elevation was a predisposing factor or consequence of colorectal adenoma (40). For IL6 and TNFα, the only available study did not find any association with risk of recurrent adenomas (38).

Given the sparse data, we prospectively examined measures of plasma MIC-1, CRP, IL6, and soluble TNF receptor 2 (sTNFR-2, also known as TNF receptor superfamily member 1B, TNFRSF1B), a surrogate marker for TNFα, with the incidence of advanced colorectal adenomas in a case–control study nested within the Nurses' Health Study (NHS).

Study population

The NHS included 121,701 U.S. registered female nurses who were of age 30 to 55 years in 1976. Detailed description of the cohort has been provided elsewhere (41). Briefly, follow-up questionnaires were administered biennially to collect and update medical, lifestyle, and other health-related information; validated food frequency questionnaires (FFQ) were completed in 1980, 1984, 1986, and every 4 years thereafter to update dietary information. The follow-up rate had been 95.6% among participants who were alive up to 2008. Between 1989 and 1990, 32,826 women returned a blood specimen on ice packs by overnight courier. The procedures for blood collection, handling and storage, have been previously summarized (42). Written informed consent was obtained from all participants, and the study protocol was approved by the Institutional Review Board at the Brigham and Women's Hospital and the Harvard T.H. Chan School of Public Health.

Selection of colorectal adenoma cases and control subjects

Women were eligible for selection as either an adenoma case subject or a control subject if they had provided a blood specimen in 1989 to 1990 and reported having at least one sigmoidoscopy or colonoscopy from 1990 through 2008 after blood donation. Women who had a history of inflammatory bowel disease, a familial polyposis syndrome, or diagnosed adenoma or cancer (except non-melanoma skin cancer) before blood draw were excluded. When a participant reported a polyp on a biennial questionnaire, we asked for her permission to obtain medical records and pathology reports. With each biennial questionnaire, we obtained records on over 90% of reported polyps. Study investigators, blinded to risk factors and other medical history, reviewed all records and extracted data on histologic type, anatomic location, and size of polyps. We classified adenoma cases into proximal colon (from cecum to splenic flexure), distal colon (descending colon and sigmoid), and rectal adenomas (rectosigmoid and rectum).

For this study, we included cases of advanced adenomas, defined as adenomas of at least 1 cm in diameter or any size with tubulovillous, villous, or high-grade dysplasia, as previously described (7). Using risk set sampling, we randomly selected one control subject (i.e., women who did not report a polyp, including hyperplastic, on endoscopy) for each case matched on date of endoscopy (i.e., during the same 2-year period), birth year, indication for endoscopy, time period of endoscopy before adenoma diagnosis, month and year of blood draw, and fasting status. A total of 1,514 women (757 case subjects and 757 control subjects) were included in this analysis.

Laboratory assays

All laboratory assays for plasma inflammatory markers were performed at the laboratory of Dr. Nader Rifai at Boston Children's Hospital (Boston, MA). We used ELISA (R&D Systems) to measure levels of MIC-1 (GDF15), IL6, and sTNFR-2, and a highly sensitive immunoturbidimetric assay (Denka Seiken Co.) to measure CRP levels in the archived prediagnostic plasma specimens. Samples from cases and their matched controls were analyzed in the same batch. Quality control samples were randomly interspersed among the case–control samples. Personnel blinded to quality control and case–control status conducted all assays.

The biomarkers were assayed in two batches over 6 years apart and drift samples were included to assess laboratory drift over time. The intraclass correlation between measurements of the two drift batches was 0.99 for MIC-1, 0.97 for CRP, 0.97 for IL6, and 0.82 for sTNFR-2. To minimize the batch effect, we corrected biomarker concentrations for measurement batch using the average batch correction method (43) with adjustment for age, body mass index (BMI), and case–control status. The mean intra-assay coefficient of variation from blinded quality control samples was 4.8% for MIC-1, 5.5% for CRP, 12.7% for IL6, and 15.9% for sTNFR-2.

Statistical analysis

We categorized plasma markers into quantiles on the basis of their distributions among control participants. Conditional logistic regression was used to estimate the ORs and 95% confidence intervals (95% CI) of advanced adenomas in relation to biomarkers. Test for trend was performed using the median value for each quintile as a continuous variable in the regression models. We assessed the potential nonlinear relationship between biomarkers and adenoma risk using stepwise restricted cubic spline analysis (44), with a P = 0.05 as the criteria for both inclusion and retention in the model. In the multivariable analyses, we adjusted for several risk factors for colorectal neoplasia. Details regarding the assessment of covariates are provided in the Supplementary Materials.

We compared the median levels of biomarkers among adenoma cases diagnosed with distinct pathologic characteristics using the Kruskal–Wallis test. To examine the independent associations between adenoma characteristics and biomarker concentrations, we performed a multivariable linear regression of log-transformed measurements of biomarkers on adenoma features.

We then examined the association between biomarker levels and adenoma risk according to pathologic features of adenoma. We also performed stratified analyses to evaluate whether the observed associations vary by lifestyle factors.

We used SAS version 9.3 (SAS Institute, Inc.) for all analyses. All statistical tests were two-sided and a P value of <0.05 was considered statistically significant.

As shown in Table 1, women diagnosed with advanced adenoma were heavier and more likely to smoke at baseline than controls. In contrast, control subjects consumed more calcium and had higher AHEI scores than cases. Plasma MIC-1, CRP, and sTNFR-2 levels were higher among cases than controls (P = 0.04, 0.01, and 0.07, respectively). On average, cases were diagnosed about 10 years after blood collection. Most cases had adenomas in the colon, especially in the distal colon (41%), whereas only 13% cases had adenomas in the rectum.

Table 1.

Baseline characteristics of participants in the Nurses' Health Study (1990)a

VariableCases (n = 757)Controls (n = 757)P
Age at blood draw, years 56.9 (6.8) 56.8 (6.7) 0.24 
Body mass index, kg/m2 25.9 (4.7) 25.4 (4.5) 0.01 
Physical activity, MET-hours/week 14.7 (16.8) 16.9 (25.2) 0.14 
Colorectal cancer in a parent or sibling, % 17 15 0.20 
History of lower gastrointestinal endoscopy, % 33 32 0.61 
Postmenopausal, % 84 84 0.70 
Current use of menopausal hormone therapy, %b 42 48 0.09 
Current multivitamin use, % 37 38 0.60 
Regular aspirin use (≥2 tablets/week), %c 39 43 0.14 
Regular NSAID use (≥2 tablets/week), %d 19 21 0.36 
Current smoker, % 14 10 0.01 
Alcohol consumption, g/d 5.6 (10.2) 4.9 (8.6) 0.78 
Calcium intake, mg/d 1001 (519) 1035 (484) 0.06 
Dietary AHEI score 44.0 (9.1) 45.0 (8.9) 0.03 
Plasma biomarker levels, median (IQR)e 
 MIC-1, ng/L 609 (494–783) 595 (488–741) 0.04 
 CRP, mg/L 1.91 (0.90–4.04) 1.56 (0.75–3.62) 0.01 
 IL6, ng/L 0.96 (0.62–1.59) 0.96 (0.59–1.58) 0.55 
 sTNFR-2, μg/L 2.68 (2.30–3.16) 2.64 (2.30–3.10) 0.07 
 Time of diagnosis since blood draw, month 118 (57) –  
Size of adenoma, mm 14.4 (9.8) –  
Multiple (≥2) adenoma, % 34 –  
Adenoma location, % 
 Proximal colon 28 –  
 Distal colon 41 –  
 Rectum 13 –  
 Multiple adenomas in ≥2 locations 18 –  
Histology of adenoma, %    
 Tubular 38 –  
 Tubulovillous, villous or high-grade dysplasia (CIS) 62 –  
VariableCases (n = 757)Controls (n = 757)P
Age at blood draw, years 56.9 (6.8) 56.8 (6.7) 0.24 
Body mass index, kg/m2 25.9 (4.7) 25.4 (4.5) 0.01 
Physical activity, MET-hours/week 14.7 (16.8) 16.9 (25.2) 0.14 
Colorectal cancer in a parent or sibling, % 17 15 0.20 
History of lower gastrointestinal endoscopy, % 33 32 0.61 
Postmenopausal, % 84 84 0.70 
Current use of menopausal hormone therapy, %b 42 48 0.09 
Current multivitamin use, % 37 38 0.60 
Regular aspirin use (≥2 tablets/week), %c 39 43 0.14 
Regular NSAID use (≥2 tablets/week), %d 19 21 0.36 
Current smoker, % 14 10 0.01 
Alcohol consumption, g/d 5.6 (10.2) 4.9 (8.6) 0.78 
Calcium intake, mg/d 1001 (519) 1035 (484) 0.06 
Dietary AHEI score 44.0 (9.1) 45.0 (8.9) 0.03 
Plasma biomarker levels, median (IQR)e 
 MIC-1, ng/L 609 (494–783) 595 (488–741) 0.04 
 CRP, mg/L 1.91 (0.90–4.04) 1.56 (0.75–3.62) 0.01 
 IL6, ng/L 0.96 (0.62–1.59) 0.96 (0.59–1.58) 0.55 
 sTNFR-2, μg/L 2.68 (2.30–3.16) 2.64 (2.30–3.10) 0.07 
 Time of diagnosis since blood draw, month 118 (57) –  
Size of adenoma, mm 14.4 (9.8) –  
Multiple (≥2) adenoma, % 34 –  
Adenoma location, % 
 Proximal colon 28 –  
 Distal colon 41 –  
 Rectum 13 –  
 Multiple adenomas in ≥2 locations 18 –  
Histology of adenoma, %    
 Tubular 38 –  
 Tubulovillous, villous or high-grade dysplasia (CIS) 62 –  

Abbreviations: AHEI, Alternative Healthy Eating Index; CIS, carcinoma in situ; CRP, C-reactive protein; IQR, interquartile range; MET, metabolic equivalent; MIC-1, macrophage inhibitory cytokine-1; NSAID, non-steroidal anti-inflammatory drug; sTNFR-2, soluble tumor necrosis factor receptor 2.

aMean (SD) is presented for continuous variables unless otherwise specified.

bPercentage is among postmenopausal women only.

cRegular use is defined as ≥2 standard (325 mg) tablets of aspirin per week.

dRegular use is defined as ≥2 tablets of NSAIDs per week.

eThe number of pairs of subjects with missing measurements: 19 for MIC-1, 3 for CRP, and 24 for IL6.

Plasma concentrations of MIC-1, CRP, IL6, and sTNFR-2 were positively correlated, with a Spearman correlation coefficient ranging from 0.19 to 0.41 (Table 2). Compared with CRP, IL6, and sTNFR-2, MIC-1 demonstrated a distinct pattern of association with age and lifestyle factors: MIC-1 levels were modestly associated with age (r = 0.48) and weakly with pack-years of smoking (r = 0.13), but not with BMI (r = 0.04), physical activity(r = 0.02), alcohol consumption (r = −0.06), or dietary score AHEI (r = 0.05). In contrast, CRP, IL6, and sTNFR-2 were less age dependent, and generally showed a weaker correlation with smoking, but a stronger correlation with BMI, alcohol consumption, and dietary AHEI score.

Table 2.

Spearman correlation coefficient of plasma inflammatory marker levels with age and lifestyle factors among control participants in the Nurses' Health Study (1990)

VariableMIC-1CRPIL6sTNFR-2AgeBMIPhysical activityPack-years of smokingAlcohol consumptionDietary AHEI score
MIC-1 0.19a 0.30a 0.38a 0.48a 0.04 0.02 0.13a −0.06 0.05 
CRP  0.41a 0.38a 0.22a 0.38a −0.07c 0.10a −0.05 −0.10a 
IL6   0.38a 0.21a 0.27a −0.06 0.05 −0.12b −0.12b 
sTNFR-2    0.26a 0.24a −0.06 0.05 −0.15a −0.10b 
Age     0.07 0.06 0.09c 0.04 0.20a 
BMI      −0.10b 0.02 −0.10b −0.12b 
Physical activity       0.01 0.17a 0.29a 
Pack-years of smoking        0.28a 0.05 
Alcohol consumption         0.21a 
Dietary AHEI score          
VariableMIC-1CRPIL6sTNFR-2AgeBMIPhysical activityPack-years of smokingAlcohol consumptionDietary AHEI score
MIC-1 0.19a 0.30a 0.38a 0.48a 0.04 0.02 0.13a −0.06 0.05 
CRP  0.41a 0.38a 0.22a 0.38a −0.07c 0.10a −0.05 −0.10a 
IL6   0.38a 0.21a 0.27a −0.06 0.05 −0.12b −0.12b 
sTNFR-2    0.26a 0.24a −0.06 0.05 −0.15a −0.10b 
Age     0.07 0.06 0.09c 0.04 0.20a 
BMI      −0.10b 0.02 −0.10b −0.12b 
Physical activity       0.01 0.17a 0.29a 
Pack-years of smoking        0.28a 0.05 
Alcohol consumption         0.21a 
Dietary AHEI score          

Abbreviations: AHEI, Alternative Healthy Eating Index; BMI, body mass index; CRP, C-reactive protein; MIC-1, macrophage inhibitory cytokine-1; sTNFR-2, soluble tumor necrosis factor receptor 2.

aP < 0.001.

b0.001 ≤ P < 0.01.

c0.01 ≤ P < 0.05.

Elevated levels of plasma MIC-1 were associated with higher risk of advanced colorectal adenoma (Table 3). Compared with women in the lowest quintile, the OR of advanced adenoma among those at the highest quintile of MIC-1 was 1.55 (95% CI, 1.03–2.32; Ptrend = 0.04), after adjusting for several potential confounders and other inflammatory markers. In spline analysis, no spline variable was selected into the model, indicating that the association did not deviate from linearity. Excluding cases diagnosed within the first 4 years after blood draw did not materially change the association (OR, 1.43; 95% CI, 0.94–2.18). Similar results were also obtained after restricting the cohort to individuals who had at least one negative endoscopy before blood draw (OR, 1.47; 95% CI, 0.86–2.53). In addition, we stratified by the time period of the prior endoscopy before adenoma diagnosis, which was one of matching factors. The results did not differ between those who had a negative endoscopy within 4 years before adenoma diagnosis and those who did not (data not shown).

Table 3.

Risk of advanced colorectal adenoma according to quintiles of plasma inflammatory marker levels in the Nurses' Health Study (1990–2008)a

BiomarkerQuintile 1Quintile 2Quintile 3Quintile 4Quintile 5Ptrend
MIC-1 
 Median, ng/L 398 505 596 707 951  
 No. of cases/controls 131/148 150/148 131/147 145/148 181/147  
 Age-adjusted OR (95% CI)b 1.00 (referent) 1.19 (0.86–1.64) 1.06 (0.75–1.49) 1.17 (0.83–1.65) 1.52 (1.06–2.18) 0.03 
 MV-adjusted OR (95% CI)c 1.00 (referent) 1.20 (0.86–1.68) 1.00 (0.70–1.42) 1.13 (0.79–1.63) 1.49 (1.01–2.18) 0.05 
 MV-adjusted OR (95% CI)d 1.00 (referent) 1.19 (0.84–1.67) 1.01 (0.70–1.44) 1.10 (0.76–1.60) 1.55 (1.03–2.32) 0.04 
CRP 
 Median, mg/L 0.43 0.91 1.70 2.99 6.32  
 No. of cases/controls 127/150 137/152 131/151 169/151 190/150  
 Age-adjusted OR (95% CI)b 1.00 (referent) 1.06 (0.77–1.47) 1.04 (0.75–1.46) 1.32 (0.96–1.83) 1.49 (1.09–2.05) 0.06 
 MV-adjusted OR (95% CI)c 1.00 (referent) 1.00 (0.71–1.40) 0.96 (0.68–1.36) 1.15 (0.81–1.63) 1.26 (0.89–1.79) 0.21 
 MV-adjusted OR (95% CI)d 1.00 (referent) 0.93 (0.66–1.33) 0.95 (0.66–1.36) 1.10 (0.77–1.59) 1.10 (0.76–1.59) 0.62 
IL6 
 Median, ng/L 0.42 0.67 0.96 1.42 2.64  
 No. of cases/controls 126/147 183/147 121/146 148/147 155/146  
 Age-adjusted OR (95% CI)b 1.00 (referent) 1.49 (1.06–2.09) 0.97 (0.68–1.38) 1.18 (0.84–1.65) 1.23 (0.88–1.71) 0.59 
 MV-adjusted OR (95% CI)c 1.00 (referent) 1.33 (0.94–1.89) 0.79 (0.54–1.16) 0.93 (0.64–1.35) 0.99 (0.69–1.42) 0.64 
 MV-adjusted OR (95% CI)d 1.00 (referent) 1.33 (0.93–1.89) 0.77 (0.52–1.14) 0.91 (0.62–1.33) 0.96 (0.65–1.42) 0.53 
sTNFR-2 
 Median, μg/L 1.97 2.38 2.64 3.01 3.71  
 No. of cases/controls 153/152 140/151 145/152 155/151 164/151  
 Age-adjusted OR (95% CI)b 1.00 (referent) 0.92 (0.66–1.28) 0.96 (0.69–1.34) 1.03 (0.74–1.44) 1.10 (0.78–1.54) 0.41 
 MV-adjusted OR (95% CI)c 1.00 (referent) 0.86 (0.61–1.21) 0.91 (0.64–1.29) 0.92 (0.65–1.31) 0.99 (0.68–1.42) 0.83 
 MV-adjusted OR (95% CI)d 1.00 (referent) 0.86 (0.60–1.23) 0.90 (0.63–1.29) 0.88 (0.61–1.28) 0.89 (0.60–1.33) 0.69 
BiomarkerQuintile 1Quintile 2Quintile 3Quintile 4Quintile 5Ptrend
MIC-1 
 Median, ng/L 398 505 596 707 951  
 No. of cases/controls 131/148 150/148 131/147 145/148 181/147  
 Age-adjusted OR (95% CI)b 1.00 (referent) 1.19 (0.86–1.64) 1.06 (0.75–1.49) 1.17 (0.83–1.65) 1.52 (1.06–2.18) 0.03 
 MV-adjusted OR (95% CI)c 1.00 (referent) 1.20 (0.86–1.68) 1.00 (0.70–1.42) 1.13 (0.79–1.63) 1.49 (1.01–2.18) 0.05 
 MV-adjusted OR (95% CI)d 1.00 (referent) 1.19 (0.84–1.67) 1.01 (0.70–1.44) 1.10 (0.76–1.60) 1.55 (1.03–2.32) 0.04 
CRP 
 Median, mg/L 0.43 0.91 1.70 2.99 6.32  
 No. of cases/controls 127/150 137/152 131/151 169/151 190/150  
 Age-adjusted OR (95% CI)b 1.00 (referent) 1.06 (0.77–1.47) 1.04 (0.75–1.46) 1.32 (0.96–1.83) 1.49 (1.09–2.05) 0.06 
 MV-adjusted OR (95% CI)c 1.00 (referent) 1.00 (0.71–1.40) 0.96 (0.68–1.36) 1.15 (0.81–1.63) 1.26 (0.89–1.79) 0.21 
 MV-adjusted OR (95% CI)d 1.00 (referent) 0.93 (0.66–1.33) 0.95 (0.66–1.36) 1.10 (0.77–1.59) 1.10 (0.76–1.59) 0.62 
IL6 
 Median, ng/L 0.42 0.67 0.96 1.42 2.64  
 No. of cases/controls 126/147 183/147 121/146 148/147 155/146  
 Age-adjusted OR (95% CI)b 1.00 (referent) 1.49 (1.06–2.09) 0.97 (0.68–1.38) 1.18 (0.84–1.65) 1.23 (0.88–1.71) 0.59 
 MV-adjusted OR (95% CI)c 1.00 (referent) 1.33 (0.94–1.89) 0.79 (0.54–1.16) 0.93 (0.64–1.35) 0.99 (0.69–1.42) 0.64 
 MV-adjusted OR (95% CI)d 1.00 (referent) 1.33 (0.93–1.89) 0.77 (0.52–1.14) 0.91 (0.62–1.33) 0.96 (0.65–1.42) 0.53 
sTNFR-2 
 Median, μg/L 1.97 2.38 2.64 3.01 3.71  
 No. of cases/controls 153/152 140/151 145/152 155/151 164/151  
 Age-adjusted OR (95% CI)b 1.00 (referent) 0.92 (0.66–1.28) 0.96 (0.69–1.34) 1.03 (0.74–1.44) 1.10 (0.78–1.54) 0.41 
 MV-adjusted OR (95% CI)c 1.00 (referent) 0.86 (0.61–1.21) 0.91 (0.64–1.29) 0.92 (0.65–1.31) 0.99 (0.68–1.42) 0.83 
 MV-adjusted OR (95% CI)d 1.00 (referent) 0.86 (0.60–1.23) 0.90 (0.63–1.29) 0.88 (0.61–1.28) 0.89 (0.60–1.33) 0.69 

Abbreviations: CI, confidence interval; CRP, C-reactive protein; MIC-1, macrophage inhibitory cytokine-1; MV, multivariable; sTNFR-2, soluble tumor necrosis factor receptor 2.

aThe number of pairs of subjects with missing measurements were excluded from the analysis: 19 for MIC-1, 3 for CRP, and 24 for IL6.

bAge-adjusted models accounted for matching factors [date of endoscopy (i.e., had to be performed during the same 2-year period), birth year, indication for endoscopy, time period of any prior endoscopy, month and year of blood draw, and fasting status].

cMultivariable-adjusted models accounted for matching factors and were adjusted for family history of colorectal cancer (yes or no), multivitamin use (yes or no), pack-years of smoking before age 30 (0, 0–7.9, ≥8), alcohol consumption (0–0.14, 0.15–1.9, 2.0–7.4, ≥7.5 g/d), body mass index (<21, 21–22.9, 23–24.9, 25–29.9, ≥30 kg/m2), physical activity (≤5, 5.1–10, 10.1–20, >20 MET-hours/week), regular aspirin/NSAID use (yes or no), postmenopausal status and hormone use (premenopausal, postmenopausal with ever or never using hormone therapy), calcium intake (in tertiles), and Alternative Healthy Eating Index (in tertiles).

dMultivariable-adjusted models were additionally adjusted for the other plasma markers omitting the main exposure (i.e., MIC-1, CRP, IL6, and sTNFR-2).

In contrast, plasma CRP, IL6, or sTNFR-2 was not associated with adenoma risk after adjusting for potential confounders and other inflammatory markers, with an OR of 1.10 (95% CI, 0.76–1.59), 0.96 (95% CI, 0.65–1.42), and 0.89 (95% CI, 0.60–1.33) comparing the highest with the lowest quintiles, respectively (Table 3).

We then compared the median biomarker concentrations between certain case subgroups defined by adenoma characteristics. As shown in Table 4, MIC-1 levels were higher among cases with multiple (≥2) adenomas than those with single adenomas (P < 0.001). Cases with large adenomas, defined by ≥1 cm diameter, also had higher MIC-1 levels than those with small adenomas (median level = 614 vs. 587 ng/L), although the test did not reach statistical significance (P = 0.13). When adenoma number, size, and histology were simultaneously included in the age-adjusted linear regression model, MIC-1 levels increased by 2.5% (95% CI, 0.4%–4.7%; P = 0.02) per each additional adenoma, and by 1.9% (95% CI, −0.8%–4.7%; P = 0.16) per 1-cm increment of adenoma size (data only shown in the text). Histology of adenoma was not associated with MIC-1 levels. A gradual increase of MIC-1 levels was also observed from cases diagnosed with rectal, distal colon to proximal colon adenomas (median levels = 568, 592, and 616 ng/L, respectively; P = 0.12). Plasma CRP, IL6, or sTNFR-2 levels did not differ by adenoma features.

Table 4.

Median (inter-quartile range) levels of plasma inflammatory markers according to characteristics of colorectal adenoma among case participants in the Nurses' Health Study (1990)a

CharacteristicMIC-1, ng/LCRP, mg/LIL6, ng/LsTNFR-2, μg/L
Number of adenoma 
 Single (n = 482) 580 (485–742) 1.94 (0.92–3.86) 0.93 (0.62–1.62) 2.69 (2.32–3.13) 
 Multiple (n = 252) 659 (517–856) 1.88 (0.78–4.45) 1.02 (0.62–1.58) 2.67 (2.26–3.22) 
P <0.001 0.89 0.61 0.91 
Size of adenoma 
 <1 cm (n = 114) 587 (474–772) 1.73 (0.84–3.60) 0.96 (0.65–1.50) 2.63 (2.37–3.03) 
 ≥1 cm (n = 613) 614 (497–783) 1.94 (0.90–4.07) 0.97 (0.62–1.59) 2.70 (2.29–3.18) 
P 0.13 0.47 0.84 0.58 
Location 
 Proximal colon (n = 206) 616 (513–788) 2.08 (0.88–3.85) 0.91 (0.61–1.50) 2.71 (2.27–3.20) 
 Distal colon (n = 298) 592 (480–753) 1.81 (0.88–4.04) 0.93 (0.60–1.50) 2.66 (2.33–3.09) 
 Rectum (n = 98) 568 (487–759) 2.00 (1.21–3.71) 1.10 (0.67–1.93) 2.65 (2.26–3.10) 
 Multiple adenomas in ≥2 locations (n = 131) 638 (508–823) 1.81 (0.75–4.46) 1.06 (0.62–1.57) 2.83 (2.32–3.33) 
P 0.12 0.79 0.16 0.30 
Histologic type 
 Tubular adenoma (n = 247) 612 (494–778) 2.00 (0.84–4.06) 0.93 (0.60–1.59) 2.72 (2.33–3.20) 
 Tubulovillous, villous adenoma or high-grade dysplasia (n = 400) 607 (489–786) 1.88 (0.91–4.15) 0.99 (0.62–1.68) 2.67 (2.32–3.13) 
P 0.91 0.36 0.35 0.63 
CharacteristicMIC-1, ng/LCRP, mg/LIL6, ng/LsTNFR-2, μg/L
Number of adenoma 
 Single (n = 482) 580 (485–742) 1.94 (0.92–3.86) 0.93 (0.62–1.62) 2.69 (2.32–3.13) 
 Multiple (n = 252) 659 (517–856) 1.88 (0.78–4.45) 1.02 (0.62–1.58) 2.67 (2.26–3.22) 
P <0.001 0.89 0.61 0.91 
Size of adenoma 
 <1 cm (n = 114) 587 (474–772) 1.73 (0.84–3.60) 0.96 (0.65–1.50) 2.63 (2.37–3.03) 
 ≥1 cm (n = 613) 614 (497–783) 1.94 (0.90–4.07) 0.97 (0.62–1.59) 2.70 (2.29–3.18) 
P 0.13 0.47 0.84 0.58 
Location 
 Proximal colon (n = 206) 616 (513–788) 2.08 (0.88–3.85) 0.91 (0.61–1.50) 2.71 (2.27–3.20) 
 Distal colon (n = 298) 592 (480–753) 1.81 (0.88–4.04) 0.93 (0.60–1.50) 2.66 (2.33–3.09) 
 Rectum (n = 98) 568 (487–759) 2.00 (1.21–3.71) 1.10 (0.67–1.93) 2.65 (2.26–3.10) 
 Multiple adenomas in ≥2 locations (n = 131) 638 (508–823) 1.81 (0.75–4.46) 1.06 (0.62–1.57) 2.83 (2.32–3.33) 
P 0.12 0.79 0.16 0.30 
Histologic type 
 Tubular adenoma (n = 247) 612 (494–778) 2.00 (0.84–4.06) 0.93 (0.60–1.59) 2.72 (2.33–3.20) 
 Tubulovillous, villous adenoma or high-grade dysplasia (n = 400) 607 (489–786) 1.88 (0.91–4.15) 0.99 (0.62–1.68) 2.67 (2.32–3.13) 
P 0.91 0.36 0.35 0.63 

Abbreviations: CRP, C-reactive protein; MIC-1, macrophage inhibitory cytokine-1; sTNFR-2, soluble tumor necrosis factor receptor 2.

aAdenoma characteristics were missing for some cases and thus the total number of cases may not add up to 757.

Next, we assessed the association of MIC-1 with adenoma risk according to the pathologic characteristics (Table 5). We found that MIC-1 levels were statistically significantly related to an increased risk of adenomas with multiplicity (Ptrend = 0.02), large size (≥1 cm, Ptrend = 0.03) or location in the proximal colon (Ptrend = 0.04). No statistically significant association was found for histologically more advanced adenomas or adenomas located in the distal colon or rectum.

Table 5.

OR (95% confidence interval) of advanced colorectal adenomas according to quartiles of plasma MIC-1 levels by adenoma characteristics in the Nurses' Health Study (1990–2008)

SubgroupQuartile 1Quartile 2Quartile 3Quartile 4Ptrend
Multiple adenoma 
 No. of cases/controlsa 50/56 46/59 58/62 98/75  
 OR (95% CI)b 1.00 (referent) 0.88 (0.50–1.56) 1.06 (0.59–1.89) 1.75 (0.98–3.13) 0.02 
Adenoma of ≥1 cm      
 No. of cases/controlsa 141/155 146/149 141/159 185/150  
 OR (95% CI)b 1.00 (referent) 1.11 (0.79–1.56) 0.99 (0.69–1.41) 1.49 (1.02–2.18) 0.03 
Proximal colon adenoma 
 No. of cases/controlsa 39/48 55/56 45/54 67/48  
 OR (95% CI)b 1.00 (referent) 1.25 (0.70–2.23) 1.06 (0.54–2.05) 1.97 (1.01–3.84) 0.04 
Distal colon adenoma 
 No. of cases/controlsa 82/74 67/78 72/78 77/68  
 OR (95% CI)b 1.00 (referent) 0.80 (0.50–1.29) 0.82 (0.50–1.36) 1.02 (0.59–1.78) 0.76 
Rectal adenoma 
 No. of cases/controlsa 25/29 28/23 16/20 29/26  
 OR (95% CI)b 1.00 (referent) 1.49 (0.63–3.52) 0.87 (0.37–2.03) 1.28 (0.54–3.04) 0.82 
Multiple adenomas in ≥2 locations 
 No. of cases/controlsa 30/31 22/28 33/30 46/42  
 OR (95% CI)b 1.00 (referent) 0.76 (0.35–1.66) 0.97 (0.47–2.02) 1.12 (0.52–2.42) 0.55 
Villous or tubulovillous adenoma or high-grade dysplasia 
 No. of cases/controlsa 100/108 91/91 87/95 122/106  
 OR (95% CI)b 1.00 (referent) 1.08 (0.72–1.61) 1.00 (0.65–1.56) 1.29 (0.82–2.04) 0.26 
SubgroupQuartile 1Quartile 2Quartile 3Quartile 4Ptrend
Multiple adenoma 
 No. of cases/controlsa 50/56 46/59 58/62 98/75  
 OR (95% CI)b 1.00 (referent) 0.88 (0.50–1.56) 1.06 (0.59–1.89) 1.75 (0.98–3.13) 0.02 
Adenoma of ≥1 cm      
 No. of cases/controlsa 141/155 146/149 141/159 185/150  
 OR (95% CI)b 1.00 (referent) 1.11 (0.79–1.56) 0.99 (0.69–1.41) 1.49 (1.02–2.18) 0.03 
Proximal colon adenoma 
 No. of cases/controlsa 39/48 55/56 45/54 67/48  
 OR (95% CI)b 1.00 (referent) 1.25 (0.70–2.23) 1.06 (0.54–2.05) 1.97 (1.01–3.84) 0.04 
Distal colon adenoma 
 No. of cases/controlsa 82/74 67/78 72/78 77/68  
 OR (95% CI)b 1.00 (referent) 0.80 (0.50–1.29) 0.82 (0.50–1.36) 1.02 (0.59–1.78) 0.76 
Rectal adenoma 
 No. of cases/controlsa 25/29 28/23 16/20 29/26  
 OR (95% CI)b 1.00 (referent) 1.49 (0.63–3.52) 0.87 (0.37–2.03) 1.28 (0.54–3.04) 0.82 
Multiple adenomas in ≥2 locations 
 No. of cases/controlsa 30/31 22/28 33/30 46/42  
 OR (95% CI)b 1.00 (referent) 0.76 (0.35–1.66) 0.97 (0.47–2.02) 1.12 (0.52–2.42) 0.55 
Villous or tubulovillous adenoma or high-grade dysplasia 
 No. of cases/controlsa 100/108 91/91 87/95 122/106  
 OR (95% CI)b 1.00 (referent) 1.08 (0.72–1.61) 1.00 (0.65–1.56) 1.29 (0.82–2.04) 0.26 

Abbreviations: CI, confidence interval; MIC-1, macrophage inhibitory cytokine-1.

aAdenoma characteristics were missing for some cases and thus the total number of cases may not add up to 757.

bMultivariable model accounted for matching factors [date of endoscopy (i.e., had to be performed during the same 2-year period), birth year, indication for endoscopy, time period of any prior endoscopy, month and year of blood draw, and fasting status] and was additionally adjusted for family history of colorectal cancer (yes or no), multivitamin use (yes or no), pack-years of smoking before age 30 (0, 0–7.9, ≥8), alcohol consumption (0–0.14, 0.15–1.9, 2.0–7.4, ≥7.5 g/d), body mass index (<21, 21–22.9, 23–24.9, 25–29.9, ≥30 kg/m2), physical activity (≤5, 5.1–10, 10.1–20, >20 MET-hours/week), regular aspirin/NSAID use (yes or no), postmenopausal status and hormone use (premenopausal, postmenopausal with ever or never using hormone therapy), calcium intake (in tertiles), and Alternative Healthy Eating Index (in tertiles).

Finally, we examined whether the association of MIC-1 with risk of adenoma varied by age and lifestyle factors (Supplementary Table S1). No statistically significant interaction was detected (Pinteraction > 0.30).

In this prospective study nested within the NHS cohort, we found that compared with the lowest quintile, the highest quintile of plasma MIC-1, but not CRP, IL6, or sTNFR-2, was positively associated with risk of advanced colorectal adenoma. This association appeared to be stronger for women with multiple, large adenomas, and adenomas located in the proximal colon. Plasma MIC-1 level itself was also related to these diagnostic features among cases. Our results suggest that MIC-1 may be a biomarker for individuals at higher risk for colorectal neoplasia.

Although elevated CRP has been associated with higher colorectal cancer risk in a recent meta-analysis (45), substantial heterogeneity was noted among studies. In contrary, several lines of evidence argue against a causal effect of CRP on colorectal cancer development. Circulating CRP levels were not associated with colonic mucosal measures of inflammation among healthy adults (46), indicating that increased CRP in the circulation does not reflect colonic inflammation and the CRP–colorectal cancer association may be explained by other factors, such as reverse causation. In our previous study, the positive association between prediagnostic CRP and colorectal cancer risk was restricted to tumors diagnosed within the first 2 years after blood draw, and an essentially null association was found for cancers diagnosed after that time window (24). This result suggests that increased CRP level in colorectal cancer patients may be not a cause but a consequence of systemic inflammation triggered by occult tumor initiation. Consistent with this hypothesis, none of the prospective studies, including our current one, found a positive association between CRP and risk of colorectal adenomas (35–39), which are early precursor lesions for invasive cancer, and thus less susceptible to the influence of reverse causation associated with tumor-induced inflammation.

For other inflammatory markers, evidence is sparse about their relationship to colorectal neoplasia. Consistent with our current findings, circulating IL6 or sTNFR-2 was not associated with risk of colorectal cancer (10, 22–24, 26, 27) or adenoma (38) in previous studies, although a positive association with colorectal cancer risk was detected for sTNFR-2 in the same cohort as the present study (23). It is possible that TNFα acts at a later stage of colorectal carcinogenesis that is not captured by examination of the first adenoma development among generally healthy women in this study.

MIC-1 is a product of activated macrophages and a novel mediator in systemic inflammation (28). High MIC-1 levels have been associated with an increased risk of cardiovascular disease (47), all-cause mortality (48), and cancers of the colorectum (33, 34), pancreas (30, 32), and prostate (31). In this study, we found that unlike CRP, IL6, and sTNFR-2, MIC-1 levels were strongly associated with age, but not with BMI. This distinct correlate pattern suggests that unlike conventional cytokines, MIC-1 may represent a distinct class of marker for inflammation and other pathologic processes that accumulate over age and are less affected by metabolic changes. Interestingly, serum MIC-1 has been associated with aging-related cognitive decline after adjusting for other inflammatory markers (e.g., CRP, IL6, and TNFα; ref. 49).

A progressive increase in serum MIC-1 levels has been observed between normal individuals, those with adenomatous polyps, and those with colorectal cancer (33), suggesting a potential role of MIC-1 in the initiation and progression of colorectal tumors. In line with our results, serum MIC-1 concentrations rose with increasing numbers of adenomas and were positively associated with risk of recurrent colorectal adenomas in a prospective study with 3 years of follow-up (40). These results corroborate the evidence base for the importance of MIC-1 throughout colorectal carcinogenesis. Building upon these findings, we also observed that MIC-1 was strongly associated with risk of large and multiple adenomas at diagnosis, although this association was observed primarily only in comparisons of the extreme quantiles. Moreover, the median time period between blood draw and adenoma diagnosis in our study was about 10 years, and we observed similar results by either excluding cases diagnosed within 4 years after blood draw or restricting the cohort to individuals with a negative endoscopy before blood draw. These findings support an association of high MIC-1 level with the earliest stages of neoplasia development, including possibly tumor initiation. In addition, we found that the positive association between MIC-1 and adenoma risk was restricted to proximal colon adenoma, and MIC levels increased among individuals eventually diagnosed with rectal, distal colon, and up to proximal colon adenomas. The potential for MIC-1 to serve as a biomarker for individuals at future risk of colorectal neoplasia, particularly for tumors in the proximal colon that are more challenging to detect endoscopically, requires further investigation (50).

Despite the strong linkage of MIC-1 expression to tumors, little is known about its role in carcinogenesis. Some evidence suggests that MIC-1 possesses both tumorigenic and antitumorigenic activity (29). MIC-1 induces apoptosis via both p53-dependent and p53-independent mechanisms (51, 52), and modulates tumor growth, possibly through its activity on NSAID-mediated cell-cycle arrest (53, 54). Recently, paracrine effects of MIC-1 expression in fibroblasts were shown to promote prostate tumor growth and invasion (55). Therefore, the dual effect of MIC-1 on tumor development is likely a function of the nature of the tumor and the interaction between tumor and its local microenvironment (29). Elevated MIC-1 may represent a marker of host antitumor immune reaction to limit tumor growth during an early stage of carcinogenesis, but when such protective mechanisms fail, the local production of MIC-1 from evolving tumors may serve as a progrowth signal to facilitate tumor progression (56).

Some limitations of our study need to be noted. First, a single measurement of plasma markers was available that may not represent their long-term levels. However, given the prospective matched design, measurement error is unlikely to differ between cases and controls, and thus can only attenuate our observed associations. Second, our analysis was focused only on women and limited largely to Caucasians. Therefore, our findings may not be generalizable to men or other ethnic populations. Third, we cannot establish whether MIC-1 plays a causal role in carcinogenesis or is primarily a biomarker for etiologic pathways associated with the initiation or progression of neoplasia. Finally, given the case–control design, our study is unable to assess the predictive capability of MIC-1 for screening. For this purpose, further prospective studies estimating the sensitivity and specificity of MIC-1 for neoplasia within a clinical screening program are needed. However, our study does provide proof-of-principle of the potential importance of chronic inflammation in the etiopathogenesis of colorectal cancer, including the development of early neoplasia (adenoma).

Our study has several strengths, including its prospective design, high follow-up rate over 18 years, detailed data on potential risk factors for both colorectal neoplasia and inflammation, and analysis of incident adenomas with confirmed diagnostic information. In particular, measures of plasma markers taken long before adenoma diagnosis minimize potential bias by early systemic alterations associated with neoplasia.

In conclusion, in this prospective study of U.S. women, elevated levels of plasma MIC-1 were associated with higher risk of advanced colorectal adenomas, especially multiple adenomas and adenomas with large size and location in the proximal colon. In contrast, we did not find evidence for an association of CRP, IL6, or sTNFR-2 with advanced colorectal adenomas. In addition, increasing adenoma number, size, and more proximal location were directly associated with increasing MIC-1 levels. Our results provide further support for the role of MIC-1 in colorectal carcinogenesis and suggest the potential use of MIC-1 to improve the detection of advanced premalignant lesions during colorectal cancer screening.

No other conflicts of interest were disclosed.

Conception and design: M. Song, K. Wu, C.S. Fuchs, E.L. Giovannucci, A.T. Chan

Development of methodology: M. Song, C.S. Fuchs, A.T. Chan

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): M. Song, C.S. Fuchs, E.L. Giovannucci, A.T. Chan

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): M. Song, R.S. Mehta, C.S. Fuchs, S. Ogino, E.L. Giovannucci, A.T. Chan

Writing, review, and/or revision of the manuscript: M. Song, K. Wu, C.S. Fuchs, S. Ogino, E.L. Giovannucci, A.T. Chan

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): C.S. Fuchs, S. Ogino, A.T. Chan

Study supervision: E.L. Giovannucci, A.T. Chan

M. Song is a trainee of the Harvard Transdisciplinary Research Center on Energetics and Cancer (TREC). The authors thank the participants and staff of the NHS for their valuable contributions.

This work was supported by the NIH [R01 CA137178 (to A.T. Chan), K24 DK098311 (to A.T. Chan), P01 CA87969 (to M.J. Stampfer), UM1 CA186107 (to M.J. Stampfer), R01 CA49449 (to S.E. Hankinson), R35 CA197735 (to S. Ogino), and 1U54CA155626 (to F.B. Hu)].

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1.
Ferlay
J
,
Soerjomataram
I
,
Ervik
M
,
Dikshit
R
,
Eser
S
,
Mathers
C
, et al
Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]
.
GLOBOCAN 2012 v10
.
Lyon, France
:
International Agency for Research on Cancer
; 
2013
.
2.
Terzic
J
,
Grivennikov
S
,
Karin
E
,
Karin
M
. 
Inflammation and colon cancer
.
Gastroenterology
2010
;
138
:
2101
14
.
3.
Itzkowitz
SH
,
Yio
X
. 
Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation
.
Am J Physiol Gastrointest Liver Physiol
2004
;
287
:
G7
17
.
4.
Algra
AM
,
Rothwell
PM
. 
Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials
.
Lancet Oncol
2012
;
13
:
518
27
.
5.
Sandler
RS
,
Halabi
S
,
Baron
JA
,
Budinger
S
,
Paskett
E
,
Keresztes
R
, et al
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer
.
N Engl J Med
2003
;
348
:
883
90
.
6.
Chan
AT
,
Giovannucci
EL
,
Schernhammer
ES
,
Colditz
GA
,
Hunter
DJ
,
Willett
WC
, et al
A prospective study of aspirin use and the risk for colorectal adenoma
.
Ann Intern Med
2004
;
140
:
157
66
.
7.
Baron
JA
,
Cole
BF
,
Sandler
RS
,
Haile
RW
,
Ahnen
D
,
Bresalier
R
, et al
A randomized trial of aspirin to prevent colorectal adenomas
.
N Engl J Med
2003
;
348
:
891
9
.
8.
Giovannucci
E
,
Rimm
EB
,
Stampfer
MJ
,
Colditz
GA
,
Ascherio
A
,
Willett
WC
. 
Aspirin use and the risk for colorectal cancer and adenoma in male health professionals
.
Ann Intern Med
1994
;
121
:
241
6
.
9.
Erlinger
TP
,
Platz
EA
,
Rifai
N
,
Helzlsouer
KJ
. 
C-reactive protein and the risk of incident colorectal cancer
.
JAMA
2004
;
291
:
585
90
.
10.
Il'yasova
D
,
Colbert
LH
,
Harris
TB
,
Newman
AB
,
Bauer
DC
,
Satterfield
S
, et al
Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort
.
Cancer Epidemiol Biomarkers Prev
2005
;
14
:
2413
8
.
11.
Gunter
MJ
,
Stolzenberg-Solomon
R
,
Cross
AJ
,
Leitzmann
MF
,
Weinstein
S
,
Wood
RJ
, et al
A prospective study of serum C-reactive protein and colorectal cancer risk in men
.
Cancer Res
2006
;
66
:
2483
7
.
12.
Aleksandrova
K
,
Jenab
M
,
Boeing
H
,
Jansen
E
,
Bueno-de-Mesquita
HB
,
Rinaldi
S
, et al
Circulating C-reactive protein concentrations and risks of colon and rectal cancer: a nested case–control study within the European Prospective Investigation into Cancer and Nutrition
.
Am J Epidemiol
2010
;
172
:
407
18
.
13.
Lee
S
,
Choe
JW
,
Kim
HK
,
Sung
J
. 
High-sensitivity C-reactive protein and cancer
.
J Epidemiol
2011
;
21
:
161
8
.
14.
Prizment
AE
,
Anderson
KE
,
Visvanathan
K
,
Folsom
AR
. 
Association of inflammatory markers with colorectal cancer incidence in the atherosclerosis risk in communities study
.
Cancer Epidemiol Biomarkers Prev
2011
;
20
:
297
307
.
15.
Wu
J
,
Cai
Q
,
Li
H
,
Cai
H
,
Gao
J
,
Yang
G
, et al
Circulating C-reactive protein and colorectal cancer risk: a report from the Shanghai Men's Health Study
.
Carcinogenesis
2013
;
34
:
2799
803
.
16.
Ito
Y
,
Suzuki
K
,
Tamakoshi
K
,
Wakai
K
,
Kojima
M
,
Ozasa
K
, et al
Colorectal cancer and serum C-reactive protein levels: a case–control study nested in the JACC Study
.
J Epidemiol
2005
;
15
Suppl 2
:
S185
9
.
17.
Zhang
SM
,
Buring
JE
,
Lee
IM
,
Cook
NR
,
Ridker
PM
. 
C-reactive protein levels are not associated with increased risk for colorectal cancer in women
.
Ann Intern Med
2005
;
142
:
425
32
.
18.
Otani
T
,
Iwasaki
M
,
Sasazuki
S
,
Inoue
M
,
Tsugane
S
. 
Plasma C-reactive protein and risk of colorectal cancer in a nested case-control study: Japan Public Health Center-based prospective study
.
Cancer Epidemiol Biomarkers Prev
2006
;
15
:
690
5
.
19.
Siemes
C
,
Visser
LE
,
Coebergh
JW
,
Splinter
TA
,
Witteman
JC
,
Uitterlinden
AG
, et al
C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study
.
J Clin Oncol
2006
;
24
:
5216
22
.
20.
Trichopoulos
D
,
Psaltopoulou
T
,
Orfanos
P
,
Trichopoulou
A
,
Boffetta
P
. 
Plasma C-reactive protein and risk of cancer: a prospective study from Greece
.
Cancer Epidemiol Biomarkers Prev
2006
;
15
:
381
4
.
21.
Allin
KH
,
Bojesen
SE
,
Nordestgaard
BG
. 
Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer
.
J Clin Oncol
2009
;
27
:
2217
24
.
22.
Heikkila
K
,
Harris
R
,
Lowe
G
,
Rumley
A
,
Yarnell
J
,
Gallacher
J
, et al
Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis
.
Cancer Causes Control
2009
;
20
:
15
26
.
23.
Chan
AT
,
Ogino
S
,
Giovannucci
EL
,
Fuchs
CS
. 
Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs
.
Gastroenterology
2011
;
140
:
799
808
.
24.
Song
M
,
Wu
K
,
Ogino
S
,
Fuchs
CS
,
Giovannucci
EL
,
Chan
AT
. 
A prospective study of plasma inflammatory markers and risk of colorectal cancer in men
.
Br J Cancer
2013
;
108
:
1891
8
.
25.
Toriola
AT
,
Cheng
TY
,
Neuhouser
ML
,
Wener
MH
,
Zheng
Y
,
Brown
E
, et al
Biomarkers of inflammation are associated with colorectal cancer risk in women but are not suitable as early detection markers
.
Int J Cancer
2013
;
132
:
2648
58
.
26.
Ho
GY
,
Wang
T
,
Gunter
MJ
,
Strickler
HD
,
Cushman
M
,
Kaplan
RC
, et al
Adipokines linking obesity with colorectal cancer risk in postmenopausal women
.
Cancer Res
2012
;
72
:
3029
37
.
27.
Ho
GY
,
Wang
T
,
Zheng
SL
,
Tinker
L
,
Xu
J
,
Rohan
TE
, et al
Circulating soluble cytokine receptors and colorectal cancer risk
.
Cancer Epidemiol Biomarkers Prev
2014
;
23
:
179
88
.
28.
Bootcov
MR
,
Bauskin
AR
,
Valenzuela
SM
,
Moore
AG
,
Bansal
M
,
He
XY
, et al
MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily
.
Proc Natl Acad Sci U S A
1997
;
94
:
11514
9
.
29.
Bauskin
AR
,
Brown
DA
,
Kuffner
T
,
Johnen
H
,
Luo
XW
,
Hunter
M
, et al
Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer
.
Cancer Res
2006
;
66
:
4983
6
.
30.
Koopmann
J
,
Buckhaults
P
,
Brown
DA
,
Zahurak
ML
,
Sato
N
,
Fukushima
N
, et al
Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers
.
Clin Cancer Res
2004
;
10
:
2386
92
.
31.
Brown
DA
,
Stephan
C
,
Ward
RL
,
Law
M
,
Hunter
M
,
Bauskin
AR
, et al
Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis
.
Clin Cancer Res
2006
;
12
:
89
96
.
32.
Wang
X
,
Li
Y
,
Tian
H
,
Qi
J
,
Li
M
,
Fu
C
, et al
Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma
.
BMC Cancer
2014
;
14
:
578
.
33.
Brown
DA
,
Ward
RL
,
Buckhaults
P
,
Liu
T
,
Romans
KE
,
Hawkins
NJ
, et al
MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma
.
Clin Cancer Res
2003
;
9
:
2642
50
.
34.
Mehta
RS
,
Song
M
,
Bezawada
N
,
Wu
K
,
Garcia-Albeniz
X
,
Morikawa
T
, et al
A prospective study of macrophage inhibitory cytokine-1 (MIC-1/GDF15) and risk of colorectal cancer
.
J Natl Cancer Inst
2014
;
106
:
dju016
.
35.
Tsilidis
KK
,
Erlinger
TP
,
Rifai
N
,
Hoffman
S
,
Hoffman-Bolton
J
,
Helzlsouer
KJ
, et al
C-reactive protein and colorectal adenoma in the CLUE II cohort
.
Cancer Causes Control
2008
;
19
:
559
67
.
36.
Chan
AT
,
Sima
CS
,
Zauber
AG
,
Ridker
PM
,
Hawk
ET
,
Bertagnolli
MM
. 
C-reactive protein and risk of colorectal adenoma according to celecoxib treatment
.
Cancer Prev Res
2011
;
4
:
1172
80
.
37.
Crockett
SD
,
Mott
LA
,
Barry
EL
,
Figueiredo
JC
,
Burke
CA
,
Baxter
GJ
, et al
C-reactive protein and risk of colorectal adenomas or serrated polyps: a prospective study
.
Cancer Prev Res
2014
;
7
:
1122
7
.
38.
Ho
GY
,
Xue
X
,
Cushman
M
,
McKeown-Eyssen
G
,
Sandler
RS
,
Ahnen
DJ
, et al
Antagonistic effects of aspirin and folic acid on inflammation markers and subsequent risk of recurrent colorectal adenomas
.
J Natl Cancer Inst
2009
;
101
:
1650
4
.
39.
Gunter
MJ
,
Cross
AJ
,
Huang
WY
,
Stanczyk
FZ
,
Purdue
M
,
Xue
X
, et al
A prospective evaluation of C-reactive protein levels and colorectal adenoma development
.
Cancer Epidemiol Biomarkers Prev
2011
;
20
:
537
44
.
40.
Brown
DA
,
Hance
KW
,
Rogers
CJ
,
Sansbury
LB
,
Albert
PS
,
Murphy
G
, et al
Serum macrophage inhibitory cytokine-1 (MIC-1/GDF15): a potential screening tool for the prevention of colon cancer?
Cancer Epidemiol Biomarkers Prev
2012
;
21
:
337
46
.
41.
Colditz
GA
,
Manson
JE
,
Hankinson
SE
. 
The Nurses' Health Study: 20-year contribution to the understanding of health among women
.
J Womens Health
1997
;
6
:
49
62
.
42.
Hankinson
SE
,
Willett
WC
,
Manson
JE
,
Hunter
DJ
,
Colditz
GA
,
Stampfer
MJ
, et al
Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women
.
J Natl Cancer Inst
1995
;
87
:
1297
302
.
43.
Rosner
B
,
Cook
N
,
Portman
R
,
Daniels
S
,
Falkner
B
. 
Determination of blood pressure percentiles in normal-weight children: some methodological issues
.
Am J Epidemiol
2008
;
167
:
653
66
.
44.
Durrleman
S
,
Simon
R
. 
Flexible regression models with cubic splines
.
Stat Med
1989
;
8
:
551
61
.
45.
Zhou
B
,
Shu
B
,
Yang
J
,
Liu
J
,
Xi
T
,
Xing
Y
. 
C-reactive protein, interleukin-6 and the risk of colorectal cancer: a meta-analysis
.
Cancer Causes Control
2014
;
25
:
1397
405
.
46.
Joshu
CE
,
Tsilidis
KK
,
Peskoe
SB
,
Giardiello
FM
,
Dluzniewski
PJ
,
Nelson
WG
, et al
The association between circulating high-sensitivity C-reactive protein concentration and pathologic measures of colonic inflammation
.
Cancer Causes Control
2014
;
25
:
409
18
.
47.
Brown
DA
,
Breit
SN
,
Buring
J
,
Fairlie
WD
,
Bauskin
AR
,
Liu
T
, et al
Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case–control study
.
Lancet
2002
;
359
:
2159
63
.
48.
Wiklund
FE
,
Bennet
AM
,
Magnusson
PK
,
Eriksson
UK
,
Lindmark
F
,
Wu
L
, et al
Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality
.
Aging Cell
2010
;
9
:
1057
64
.
49.
Fuchs
T
,
Trollor
JN
,
Crawford
J
,
Brown
DA
,
Baune
BT
,
Samaras
K
, et al
Macrophage inhibitory cytokine-1 is associated with cognitive impairment and predicts cognitive decline - the Sydney Memory and Aging Study
.
Aging Cell
2013
;
12
:
882
9
.
50.
Lieberman
D
. 
Progress and challenges in colorectal cancer screening and surveillance
.
Gastroenterology
2010
;
138
:
2115
26
.
51.
Li
PX
,
Wong
J
,
Ayed
A
,
Ngo
D
,
Brade
AM
,
Arrowsmith
C
, et al
Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression
.
J Biol Chem
2000
;
275
:
20127
35
.
52.
Baek
SJ
,
Kim
KS
,
Nixon
JB
,
Wilson
LC
,
Eling
TE
. 
Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities
.
Mol Pharmacol
2001
;
59
:
901
8
.
53.
Graichen
R
,
Liu
D
,
Sun
Y
,
Lee
KO
,
Lobie
PE
. 
Autocrine human growth hormone inhibits placental transforming growth factor-beta gene transcription to prevent apoptosis and allow cell cycle progression of human mammary carcinoma cells
.
J Biol Chem
2002
;
277
:
26662
72
.
54.
Kim
JS
,
Baek
SJ
,
Sali
T
,
Eling
TE
. 
The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15
.
Mol Cancer Ther
2005
;
4
:
487
93
.
55.
Bruzzese
F
,
Hagglof
C
,
Leone
A
,
Sjoberg
E
,
Roca
MS
,
Kiflemariam
S
, et al
Local and systemic protumorigenic effects of cancer-associated fibroblast-derived GDF15
.
Cancer Res
2014
;
74
:
3408
17
.
56.
Husaini
Y
,
Qiu
MR
,
Lockwood
GP
,
Luo
XW
,
Shang
P
,
Kuffner
T
, et al
Macrophage inhibitory cytokine-1 (MIC-1/GDF15) slows cancer development but increases metastases in TRAMP prostate cancer prone mice
.
PLoS ONE
2012
;
7
:
e43833
.